NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CDK, NTRK, PI3K, ROS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have a clinically actionable alteration in NTRK, ROS1, the CDK pathway, or PI3K pathway in both a brain metastasis and extracranial site
Exclusions: Patients with leptomeningeal involvement

Comments are closed.

Up ↑